[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546465":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":111,"collaborators":19,"id":113,"slug":114,"hasResults":115,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":19,"eligibilityCriteria":119,"healthyVolunteers":115,"sex":120,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":19,"studyType":126,"phases":127,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":43,"whyStopped":19,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},{"fullName":5,"class":6},"Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DF-003","EXPERIMENTAL","Oral (PO) doses of 140 mg DF-003 on Days 1, 2, and 3 followed by a maintenance dose of 45 mg DF-003 once daily (QD) starting on Day 4 through Day 28. DF-003 will be administered PO with approximately 240 mL of water in the morning once daily for 28 consecutive days.",[13],"Drug: DF-003",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","140 mg on Days 1, 2, and 3 followed by a maintenance dose of 45 mg QD starting on Day 4 through Day 28. DF-003 will be administered PO with approximately 240 mL of water in the morning once daily for 28 consecutive days.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Kenneth Truitt, MD","CONTACT","732-221-7104","kenneth.truitt@drug-farm.com",[27,41,60,77,96],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":19},"National Institutes of Health Clinical Center","WITHDRAWN","Bethesda","Maryland","20892","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-77.10026,38.98067,{"lat":39,"lon":38},{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":33,"countryCode":34,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"Duke Eye Center - Duke University Hospital","RECRUITING","Durham","North Carolina","27705",{"type":36,"coordinates":48},[49,50],-78.89862,35.99403,{"lat":50,"lon":49},[53,57],{"name":54,"role":23,"phone":55,"phoneExt":19,"email":56},"Ethel Cuenca","919 660 3522","ethel.garcia@duke.edu",{"name":58,"role":59,"phone":19,"phoneExt":19,"email":19},"Oleg Alekseev, MD, PhD","PRINCIPAL_INVESTIGATOR",{"facility":61,"status":43,"city":62,"state":63,"zip":64,"country":33,"countryCode":34,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"John A. Moran Eye Center - University of Utah Health","Salt Lake City","Utah","84132",{"type":36,"coordinates":66},[67,68],-111.89105,40.76078,{"lat":68,"lon":67},[71,75],{"name":72,"role":23,"phone":73,"phoneExt":19,"email":74},"Lucia Lucci","801-585-6647","lucia.lucci@hsc.utah.edu",{"name":76,"role":59,"phone":19,"phoneExt":19,"email":19},"Kathleen Digre, MD",{"facility":78,"status":43,"city":79,"state":80,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Save Sight Institute - University of Sydney Eye Hospital","Sydney","New South Wales","2000","Australia","AU",{"type":36,"coordinates":85},[86,87],151.20732,-33.86785,{"lat":87,"lon":86},[90,94],{"name":91,"role":23,"phone":92,"phoneExt":19,"email":93},"Sarah Hussain","+61 2 9382 7300","Sarah.hussain@sydney.edu.au",{"name":95,"role":59,"phone":19,"phoneExt":19,"email":19},"John Grigg, MBBS, MD, FRANZCO FRACS",{"facility":97,"status":43,"city":98,"state":19,"zip":99,"country":100,"countryCode":101,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Peking Union Medical College Hospital","Beijing","100730","China","CN",{"type":36,"coordinates":103},[104,105],116.39723,39.9075,{"lat":105,"lon":104},[108],{"name":109,"role":23,"phone":19,"phoneExt":19,"email":110},"Prof. Sui Ruifang","hrfsui@163.com",{"type":112,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100546465","phase-1-evaluating-the-safety-and-tolerability-of-orally-administered-df-003-in-rosah-syndrome-patients-100546465",false,"NCT06395285","Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients","A Phase Ib, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered DF-003 in ROSAH Syndrome Patients","Inclusion Criteria:\n\n1. Sufficient understanding of the purpose and procedures required for the study.\n2. Body mass index (BMI) of 18.0 to 35.0 kg\u002Fm2, inclusive.\n3. Genetic testing for ALPK1 mutations that has been shown to be associated with ROSAH syndrome (e.g. T237M or Y254C, or T237A mutations).\n4. Signs of uveitis (anterior and\u002For posterior) in the eye (e.g. macula edema, optic nerve edema, retinal vasculitis, or retinal vascular leakage).\n5. Patients must be deemed healthy except for diagnosis of ROSAH syndrome and its clinical manifestation.\n6. Patients must be at least 18 years of age but no older than 65 years of age at the time of Screening.\n\nExclusion Criteria:\n\n1. Males who plan to father a child or donate sperm while enrolled in this study or within 90 days after the last dose of study drug.\n2. Females who are pregnant, breastfeeding, planning to become pregnant, or planning to donate eggs while on study medication or within 90 days after the last dose of study drug.\n3. Use of any of the following prohibited medications:\n\n   * Agents that are known to have systemic anti-inflammatory responses or high risk for nephrotoxicity or hepatotoxicity\n   * Moderate CYP3A4 inhibitors: e.g., amiodarone, amprenavir, conivaptan, delavirdine, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, miconazole, verapamil, grapefruit juice, cat's claw (Dolichandra unguis-cati), Echinacea augustifolia, wild cherry, chamomile, licorice\n   * Strong CYP3A4 inhibitors: e.g., ceritinib, clarithromycin, cobicistat, elvitegravir\u002Fritonavir, idelalisib, indinavir\u002Fritonavir, itraconazole, ketoconazole, lopinavir\u002Fritonavir, nefazodone, nelfinavir, paritaprevir\u002Fritonavir, ombitasvir\u002Fparitaprevir\u002Fritonavir (and\u002For dasabuvir), posaconazole, ritonavir, saquinavir\u002Fritonavir, telithromycin, tipranavir\u002Fritonavir, voriconazole.\n   * Strong CYP3A4 inducers: apalutamide, carbamazepine, enzalutamide, ivosidenib, lumacaftor\u002Fivacaftor, mitotane, phenytoin, rifampin, St. John's wort.\n   * Digoxin\n   * Agents known to cause Torsade de Pointes: Disopyramide, procainamide, quinidine, sotalol, azithromycin, clarithromycin, erythromycin, ciprofloxacin, levofloxacin, moxifloxacin, fluconazole, ketoconazole, pentamidine, voriconazole, haloperidol, thioridazine, ziprasidone, citalopram, escitalopram, dolasetron, droperidol, granisetron, and ondansetron\n   * Investigational agents (small molecules and oligonucleotides), vaccines, or invasive medical devices within 28 days (4 weeks, or 5 half-lives, whichever is longer) prior to enrollment or having received a biological product within 6 months prior to enrollment.\n4. History of significant hypersensitivity to products related to DF-003 (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs.\n5. Recent (within 3 months prior to screening) or acute changes in the following laboratory values:\n\n   * Platelet count ≤ 120,000\u002Fmm3, or\n   * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> ULN\n   * Bilirubin (total, direct) \\> ULN or\n   * International Normalization Ratio (INR) \\> ULN, or\n   * Serum albumin less than the lower limit of normal, or\n   * Estimated creatinine clearance \\\u003C 70 mL\u002Fmin\u002F1.73 m2 at Screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, or\n   * Hemoglobin A1c (HbA1c) \\> 8%.\n6. Moderate or severe hepatic impairment (categorized as Child-Pugh class B and C, respectively, on the Child-Pugh Score for Cirrhosis Mortality)","ALL","18 Years","65 Years",{"count":124,"type":125},12,"ESTIMATED","INTERVENTIONAL",[128],"PHASE1","The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.",[131],"ROSAH",[133,134,135,136,137,138,139,140],"ROSAH syndrome","alpha-protein kinase 1","cone-rod dystrophy","macular edema","papillary edema","retinal dystrophy","uveitis","T237M","2026-06-03",{"date":143,"type":144},"2026-06-05","ACTUAL",{"date":146,"type":144},"2025-05-27",{"date":148,"type":125},"2026-11",{"name":5,"class":6},5]